Dr. Thomas Boat Named Executive Associate Dean at UC College of Medicine
Boat will be responsible for operational oversight and strategic planning of all activities within the
Im delighted that Tom has accepted my invitation to join the leadership team, said David Stern, MD, dean of the college and vice president for health affairs at the UC Academic Health Center. Toms extraordinary experience with the clinical operations at Cincinnati Childrens and the
Boat stepped down in April 2007 after 14 years as chair of the UC department of pediatrics and director of the Cincinnati Children's Research Foundation. He remains on staff at Cincinnati Children's
Im eager to work with colleagues in the clinical departments at the
A pediatric pulmonologist by training, Boat worked early in his career to define the pathophysiology of airway dysfunction and develop more effective therapies for chronic lung diseases of childhood, such as cystic fibrosis.
Boat joined Cincinnati Children's in 1993, after serving as chairman of pediatrics at the
Boat is a member of the
Related Stories
Study: Additional radiation for liver cancer does not increase toxicity
March 10, 2026
New research led by University of Cincinnati Cancer Center researchers published in the American Journal of Clinical Oncology found external beam radiation therapy (EBRT) is safe to administer to patients with liver cancer even after they undergo a targeted internal radiation therapy called Y90.
Phase 1 trial tests probiotic treatment for radiation side effects in the gut
March 9, 2026
The University of Cincinnati Cancer Center’s Bailey Nelson, MD, has been awarded a $50,000 pilot grant from the Cancer Center to open a Phase 1 trial testing if a probiotic supplement can reduce gastrointestinal symptoms for patients undergoing whole pelvis radiotherapy.
Is uACR the key to cardiovascular and kidney disease prevention?
March 8, 2026
As a precision biomarker, the urinary albumin-to-creatinine ratio (uACR) can guide physicians toward personalized, patient-centered prevention and treatment of both cardiovascular disease (CVD) and chronic kidney disease (CKD), according to new data published in the Journal of Internal Medicine.